Comparative Pharmacology
Head-to-head clinical analysis: WYAMYCIN S versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WYAMYCIN S versus ZMAX.
WYAMYCIN S vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic